Treatment of Epstein-Barr Induced Hepatitis with High Dose Intravenous Vitamin C: A Case Report.
Journal
Integrative medicine (Encinitas, Calif.)
ISSN: 1546-993X
Titre abrégé: Integr Med (Encinitas)
Pays: United States
ID NLM: 101196303
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
pmc-release:
01
09
2024
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Vitamin C has been previously studied for use with acute and chronic Epstein-Barr Virus (EBV) and hepatitis C. However, it has never been evaluated for its impact on EBV induced hepatitis. In this case report, we present a patient's history with EBV induced hepatitis treated with high dose vitamin C. A 36-year-old female presented to the National University of Natural Medicine Health Center with reactivated EBV-induced viral hepatitis. She reported severe fatigue, brain fog, maintenance and initiation insomnia, periocular hyperpigmentation, blurry vision, and decreased concentration. The patient's diagnosis was confirmed with a diagnostic evaluation of her EBV titers and liver enzymes, all of which were elevated. After assessing for contraindications, the patient was treated with intravenous (IV) vitamin C starting at a 10g dose and increasing weekly for 3 weeks to a dose of 25g. After 12 weeks of treatment with high dose IV vitamin C, as well as other immune-supportive nutrient therapy, the patient reported a decrease in fatigue severity, brain fog, vision disturbances, exercise limitations, and insomnia severity. We recommend that physicians consider the administration of high-dose IV vitamin C for all concurrent cases of EBV and hepatitis in both acute and chronic conditions. As recognition of reactivated viral infections grows, high-dose IV vitamin C for other latent viral infections such as COVID-19, cytomegalovirus, herpes simplex, varicella zoster, and HIV should be considered.
Types de publication
Case Reports
Langues
eng
Pagination
24-27Informations de copyright
Copyright © 2023 InnoVision Professional Media Inc.
Déclaration de conflit d'intérêts
Conflict of Interest The authors do not have any conflicts of interest.
Références
Proc Natl Acad Sci U S A. 1971 Nov;68(11):2678-81
pubmed: 4941984
Med Sci Monit. 2014 May 03;20:725-32
pubmed: 24793092
Front Immunol. 2020 Oct 28;11:574029
pubmed: 33193359
Molecules. 2019 Mar 12;24(5):
pubmed: 30871092
Pak J Pharm Sci. 2022 Mar;35(2(Special)):619-625
pubmed: 35668562
Science. 2022 Jan 21;375(6578):296-301
pubmed: 35025605
Clin Exp Med. 2010 Mar;10(1):15-20
pubmed: 19779966
Nutrients. 2017 Nov 03;9(11):
pubmed: 29099763
Antioxid Redox Signal. 2013 Dec 10;19(17):2068-83
pubmed: 23581713
Nat Commun. 2022 Apr 5;13(1):1818
pubmed: 35383168
Biomolecules. 2021 Sep 18;11(9):
pubmed: 34572593
Gastroenterol Hepatol Bed Bench. 2017 Spring;10(2):147-149
pubmed: 28702140
BMC Public Health. 2020 Jun 12;20(1):912
pubmed: 32532296
Semin Liver Dis. 1984 Nov;4(4):301-6
pubmed: 6098015
Altern Med Rev. 2002 Oct;7(5):389-403
pubmed: 12410623
Int J Mol Med. 2008 Oct;22(4):541-5
pubmed: 18813862
Altern Ther Health Med. 2023 Jul;29(5):82-85
pubmed: 37295004
J Clin Pathol. 2019 Oct;72(10):651-658
pubmed: 31315893
Medicine (Baltimore). 2021 May 14;100(19):e25876
pubmed: 34106642
Nutrients. 2019 Oct 09;11(10):
pubmed: 31601028
Neuroimmunomodulation. 2017;24(2):67-73
pubmed: 28934729
J Infect Dis. 2008 Aug 1;198(3):318-23
pubmed: 18544038
Obstet Gynecol. 1998 Oct;92(4 Pt 2):642-4
pubmed: 9764645